Cargando…
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins that seem undruggable using the traditional drug...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053963/ https://www.ncbi.nlm.nih.gov/pubmed/36986673 http://dx.doi.org/10.3390/pharmaceutics15030812 |